Skip to content

A real-world study of shuganjieyu capsules for the treatment of male sexual dysfunction

A real-world study of Liver relief capsules for the treatment of male sexual dysfunction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300071901
Enrollment
Unknown
Registered
2023-05-29
Start date
2023-05-31
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Male sexual dysfunction with depressive states

Interventions

Shuganjieyu capsule group:In the basic treatment plan, receive Shuganjieyu capsules for 8 weeks
None-shuganjieyu capsule group:Basic treatment without Shuganjieyu capsules

Sponsors

Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1.Meet Western diagnostic criteria for erectile dysfunction and/or premature ejaculation 2.Meet the TCM diagnostic and differentiation criteria for erectile dysfunction and/or premature ejaculation 3.18 points= Screening Period Hamilton Depression Scale-17 (HAMD-17)=24 points 4.Age 18~50 years old (including 18 and 50 years old) 5.Voluntarily sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with severe cardiopulmonary dysfunction, as well as serious primary diseases of other systems such as heart, liver, and kidney 2.premature ejaculation or erectile dysfunction caused by a history of substance abuse 3.inflammation of the reproductive system, urinary stones, excessive foreskin, dysfunction of sexual partners 4.external genital hypoplasia or history of trauma or surgery 5.Those who have taken antidepressants, anxiolytics or other psychotropic drugs in the past 4 weeks or are currently taking, or in-hospital preparations, proprietary Chinese medicines or decoctions with similar effects 6.Those who have participated in clinical trials of other drugs in the past three months 7.The investigators believe that others are not suitable to participate in this clinical trial.

Design outcomes

Primary

MeasureTime frame
The change from baseline in the total score of the HAMD-17 over 8 wees of treatment;

Secondary

MeasureTime frame
The change from baseline in the total score of the HAMD-17 over 4 wees of treatment;The change in the Hamilton Anxiety Scale (HAMA) total score from baseline;Change in total erectile function index (IIEF-5) score from baseline;Change in the total score of the Premature Ejaculation Diagnostic Tool Scale (PEDT) from baseline;Change in the total score of the Health Questionnaire (SF-36) from baseline;

Countries

China

Contacts

Public ContactWang Bin

Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine

dayiwangbin@sina.com+86 139 1110 3953

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026